IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

📊 Approval moversGordon Liu100%

Study Finds 33-Fold Rise in BPC-157 Use Despite Limited Safety Data — 3dBPC-157, an unapproved peptide backed by RFK Jr. and often used with TB-500 as the “Wolverine stack,” is being consumed across a wide range of conditions in the gray market, with new-user numbers rising 33-fold from 2020 to 2026 and regulation still unresolved as the FDA weighs compounding despite safety concerns. Researchers warn that real-world use is hard to track, 1,039 documented patients exist, and there is no solid evidence that the peptide improves healing or pain, underscoring safety risks amid burgeoning popularity.

FDA panel backs BPC-157 access, Hims shares surge — Jul 23, 2026An FDA advisory panel recommended adding BPC-157 to the list eligible for pharmacy compounding, a move investors interpreted as a boost to Hims & Hers' telehealth and peptide offerings, with the stock jumping about 10–11% across reports. The company, valued around $8.1 billion, has faced insider selling in the past quarter, and regulators’ signaling comes as it positions itself in a growing peptide therapy market.

FDA Panel Recommends Loosening Peptide Compounding RulesHealth — Jul 20, 2026The FDA Pharmacy Compounding Advisory Committee is set to review seven peptide compounds, including BPC-157 and TB-500, to decide whether licensed pharmacies can make them, amid rising social-media-driven interest and largely unclear evidence of safety and effectiveness. Regulators caution the evidence base is limited as demand grows, with endorsements from public figures fueling interest and some users reporting benefits.